The changing landscape of diabetes management is witnessing a exciting shift, driven by novel incretin-based therapies. Presently, semaglutide has achieved considerable recognition, but competing medications like tirzepatide, retatrutide, and cagrilintide are set to influence the future. Tirzepatide, a dual GIP and GLP-1 target agonist, delivers… Read More